BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease ...Middle East

WUXI, China, June 21, 2023 /PRNewswire/ -- BioCity Biopharma, a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutics for cancer and autoimmune disorders, today announced the initiation of a randomized,...

Hence then, the article about biocity announces initiation of a phase 2 trial for sc0062 a promising eta receptor antagonist for chronic kidney disease was published today ( Thursday 22/06/2023 - 03:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease )

Also on site :

• Joseph Duggar's Wife Kendra Duggar's Mugshot Revealed After Arrest
• The Wailers and The Pogues Confirm Australian Tours Despite Bluesfest Collapse
• Numbrix 9 - March 21